Huakang Biomedical Holdings Co., Ltd. is a medical device group focusing on R&D, production and sales of various in vitro diagnostic reagents in China. With our knowledge and experience, the Group focuses on the male infertility in vitro diagnostic reagent market in China. According to the Insight Consulting Report, in terms of procurement value for medical institutions, we ranked third among Chinese male infertility in vitro diagnostic reagents in 2017, accounting for 14.3% of the market share. We have developed a diversified product portfolio of male infertility in vitro diagnostic reagents, which registered the highest number of products with the China Food and Drug Administration and the provincial Food and Drug Administration among all manufacturers in 2017. One of our parasite series detection reagents is one of only two in vitro diagnostic reagents for liver schistosomiasis that has been approved by the China Food and Drug Administration for production and sale in China. Shenzhen Huakang Biomedical Engineering Co., Ltd. (previously known as Shenzhen Moon Bay Biotechnology Co., Ltd. and Shenzhen Nan Fung Biotechnology Co., Ltd.), a limited company established on June 26, 1992 in accordance with Chinese law, is a wholly-owned subsidiary of the Company. Our in vitro diagnostic reagent product portfolio includes: (i) In vitro diagnostic reagents for male infertility (ii) Parasite series test reagents and (iii) A combination of in vitro diagnostic reagents including EBV detection reagents. R & D capability is one of our main competitive advantages. In 2011, we were first recognized as a “National High-tech Enterprise” by relevant Chinese government agencies. We sell our products in China through direct sales and our distributors to hospitals and medical institutions, which use our products for clinical diagnostic tests.